Latest Capital Markets News

Australian Unity Limited reported increased revenue for the half-year ending December 2025, but earnings declined sharply due to inflationary pressures and ongoing transformation investments. The company also completed a leadership transition and strengthened its balance sheet.

NEXTDC has reported a robust first half of FY26, with strong revenue and earnings growth underpinned by a surging forward order book and expanded capital expenditure plans.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Hiremii Limited has reported a record half-year revenue of $16.1 million, boosted by its acquisition of Prince Migration and advances in its AI recruitment platform. Despite a modest loss, the company is positioning itself for growth through technology innovation and strategic capital raises.

Light & Wonder, Inc. reported robust full-year 2025 financial results, highlighted by record revenues, strong cash flow growth, and a major litigation settlement. The company also completed its transition to a sole ASX listing and returned $877 million to shareholders through share repurchases.

Euroz Hartleys Group Limited reported a robust half-year result for December 2025, with net profit more than doubling to $13.84 million, driven by strong growth in equity capital markets and advisory fees.

Thorney Technologies reported a sharply reduced half-year profit amid challenging market conditions but extended its share buyback to support shareholder value.

Aspermont Limited has announced a significant security consolidation, reducing its ordinary shares on issue from nearly 2.91 billion to just over 11.6 million, aiming to streamline its capital structure and potentially enhance market liquidity.

TrivarX Limited reported a $1.26 million half-year loss as it completed the acquisition of Stabl-Im brain imaging IP and validated its mental health screening technology in veterans. The company raised $4.2 million to fund clinical development and expand its diagnostic portfolio.

QEM Limited confirms a $1.442 million capital raising via placement, addressing ASX queries on disclosure timing and compliance. The company clarifies board approvals and trading halt details, reinforcing its adherence to continuous disclosure obligations.

OncoSil Medical has reported record dose sales and cash receipts in the first half of FY26, supported by encouraging clinical trial results and expanded European market penetration.